Summary
Samenvatting van alle colleges - Metabolism and Toxicology (WBFA016-05)
- Course
- Institution
Summary of all Metabolism and Toxicology courses given at the University of Groningen
[Show more]
Seller
Follow
sarahwierda
Content preview
Metabolism and ToxicologyLecture 1: Introduction (van der Graaf)
Metabolism: chemical transformation that compounds undergo in the body body do compound.
Toxicology: adverse effects of chemicals on organisms compound to body.
Paracetamol is a very lipophilic compound. It is a save painkiller but deadly with a high dose (ong. 10
times the maximum daily dose = 30 gram)
Absorption and elimination
- Lipophilic compounds pass membranes and be absorbed.
- Ionized compounds do not pass membranes easy anymore.
- Water-soluble compounds difficult to absorb but are easily excreted.
- Fat-soluble compounds absorbed easy but can keep circulating in the body for a long
time.
Lipophilic compounds can bind to proteins, to get soluble protein too big to pass filter slows
clearance.
- Albumin: plasma protein, not filtered in glomerulus.
Compounds need to be hydrophilic/water-soluble to be excreted. Lipophilic drugs need to be
metabolised to make it water-soluble in order to be eliminated.
Toxicity: metabolism leads to reactive metabolites.
Metabolism of paracetamol
- Normal pathway: Paracetamol is converted to
hydrophilic compound which is easy to excrete.
- Toxic pathway: Paracetamol is metabolized to an N-
hydroxyl metabolite unstable, so it changes to NAPQI
toxic.
Normal pathway is faster will be chosen first. When all
routes are saturated toxicity.
Toxification / bioactivation: metabolite more toxic than parent compound.
Detoxification: metabolite less toxic than parent compound.
Adverse effect: any unwanted effect of a drug that interferes with the normal function and
adaptability of the body to the environment.
Undesirable effect: on/off target
- On-target toxicity: due to exaggerated pharmacological effect or on same receptor but on
different tissue. On same receptor.
- Off-target toxicity: via completely different mechanism (different target) than the
pharmacological effect. Effect on the incorrect receptor.
1
,Targets for toxins:
- Receptors
- Proteins (enzymes/transporters)
- Membrane-lipids
- DNA/RNA (can lead to tumors)
- Ca2+ homeostasis
- Ion channels
- Mitochondria (damage no energy)
Immunotoxicity: toxic effects by immune system, response to damage somewhere in the body.
- Due to toxic effects on immune system itself: toxic effect on B or T lymphocytes.
- Due to suppression/stimulation of the immune system.
Same dose ≠ same exposure
These can all affect the exposure, even in the dose is not different.
- Differences in exposure routes.
- Species/interindividual differences in ADME.
- Accumulation.
- Time (dose*time).
- Interactions (induction/inhibition).
Toxicity is determined by:
These determine the risks and the safety of the compound.
- Characteristics of the compound: hazard Compound potentially has an adverse effect.
- Amount/dose/concentration: degree of exposure to the hazard.
Toxicity depends on the exposure (= AUC of the concentration-time curve).
Parameters
- LD50: dose needed to kill 50% of population. Low = toxic.
- TD50: dose needed for 50% of max toxic effect / where 50% of population shows toxic effect.
- TC50: plasma concentration for 50% of max toxic effect / where 50% of pop shows toxic
effect.
- ED50: dose for 50% of desired effect / when 50% of population shows desired effect.
- EC50: plasma concentration for 50% of desired effect / when 50% of population shows
desired effect.
LOAEL: Lowest Observed Adverse Effect Level first tested dose/concentration that gives toxic
effect.
NOAEL: No Observed Adverse Effect Level: just below LOAEL.
ADI: acceptable daily intake.
Risk assessment
- Hazard: anything that can cause harm (biological property/potential).
- Risk: greatness of chance that hazard will harm someone (chance on toxicity.
Measures for safety
- Therapeutic index: TD50 / ED50.
- Margin of safety MOS: TD1 / ED99
2
,Drug testing
Toxicity is tested first in vitro on animals on healthy people on patients
Toxicology in drug development
- Research phase: screening for toxicology/metabolism (in vitro).
- Development phase: ADME (in vitro + in vivo).
- Clinical phase: human PK/toxicity/safety.
- Post-marketing: side effects, pharmacovigilance, PMS.
ADR’s are a major clinical problem.
When a drug is put on the market, the safety data is limited.
Lareb: the central collection point for all side effects of pharmaceutical drugs in the Netherlands.
REACH: Registration, Evaluation and Authorization of CHemical substances. Data about safe use of
chemical substances. European community regulations.
3
, Lecture 2: ADME & Toxicokinetics (Olinga)
ADME determines the exposure to the final toxic compound.
Toxicity
- Local toxicity: harmful without being absorbed.
- Systemic toxicity: harmful after uptake in the systemic circulation.
Bioavailability: fraction of dose that reaches the systemic circulation. Decreased by the first pass
effect (metabolism in the intestine and liver).
- Bioavailability = AUCoral/AUCi.v.
Absorption takes place in the epithelial cells.
Membrane transport
Membranes are lipophilic hydrophobic compounds are taken up easily. Hydrophilic compounds
are taken up via transporters.
- Passive transport: due to concentration difference. Via simple diffusion, a channel, or a
carrier. Lipophilic drugs can diffuse, hydrophilic drugs need to be carrier mediated.
- Active transport: against electrochemical gradient energy required. Transport through a
channel.
Absorption in GI
Depends on:
- pH (varies from 2-7).
- Blood flow.
- Metabolism in intestinal epithelial.
- Transporters in intestinal epithelium.
- Nutritional status.
- Intestinal contractions.
- Bacteria (metabolism, bioactivation, detoxification).
Surface small intestine = 250 m2.
Compound properties that affect uptake
- Lipophilicity
- Pka
- Affinity for uptake carriers
- Size
- Solubility
- Affinity for metabolic enzymes.
- Affinity for excretion carriers (P-gp).
Factors influencing intestinal toxicity (exposure)
- High concentrations in intestinal lumen after oral administration.
- Degree of uptake/excretion in intestinal epithelium.
- Metabolism (bacteria, through wall epithelial cells, pH)
Enterohepatic circulation: compound is metabolised in the liver excreted back into GI tract
taken up by the liver again.
4
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller sarahwierda. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $7.17. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
79271 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now